Assist
Brief description of study
The purpose of this study is to evaluate the safety and efficacy of atrasentan vs placebo while on background therapy with SGLT2i in subjects with IgAN. The primary efficacy assessment is the change from baseline in proteinuria at week 12. Individual subject participation duration: up to 64 weeks for subjects completing the SGLT2i run-in period and 56 weeks for subjects who do not participate in the run-in period. Treatment duration: 36 weeks of treatment with investigational product .
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
